What is eScreen?
Founded in 1998 and headquartered in Kansas City, Missouri, eScreen, Inc. specializes in comprehensive drug testing services. The company offers a range of solutions including urine, oral fluid, and hair drug testing, complemented by its proprietary Quantisal Lab Oral Fluid Collection Device. eScreen's commitment to innovation and service delivery has positioned it as a key player in the workplace safety and compliance sector, providing essential tools for employers to maintain drug-free environments.
How much funding has eScreen raised?
eScreen has raised a total of $8M across 1 funding round:
Series B
$8M
Series B (2008): $8M with participation from The Carlyle Group
Key Investors in eScreen
The Carlyle Group
The Carlyle Group is a global investment firm with a broad focus on private equity, venture and growth capital, real estate, and leveraged finance. Their extensive experience across diverse markets suggests a strategic approach to supporting companies like eScreen in their growth phases.
What's next for eScreen?
The substantial enterprise-level funding eScreen has garnered indicates a strategic phase of scaling and potential market expansion. This capital infusion is likely to fuel advancements in its testing technologies, enhance its service delivery infrastructure, and potentially broaden its market reach. The company's focus on strategic investment suggests a move towards solidifying its competitive advantage and exploring new avenues for growth within the drug testing and occupational health industry.
See full eScreen company page
